GSK plc

NYSE:GSK Stock Report

Market Cap: US$68.8b

GSK Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NYSE:GSK Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
20 Dec 24BuyUS$31,680Vishal SikkaIndividual937US$33.81
20 Dec 24BuyUS$9,162Hal BarronIndividual271US$33.81
20 Dec 24BuyUS$9,162Harry DietzIndividual271US$33.81
20 Dec 24BuyUS$9,162Anne BealIndividual271US$33.81
20 Dec 24BuyUS$73,840Charles BancroftIndividual2,184US$33.81
20 Dec 24BuyUS$9,162Tsun-Huei LeeIndividual271US$33.81
20 Dec 24BuyUS$9,196Elizabeth AndersonIndividual272US$33.81
20 Dec 24BuyUS$9,162Jesse GoodmanIndividual271US$33.81
23 Sep 24BuyUS$31,702Vishal SikkaIndividual773US$41.01
23 Sep 24BuyUS$9,187Hal BarronIndividual224US$41.01
23 Sep 24BuyUS$9,187Harry DietzIndividual224US$41.01
23 Sep 24BuyUS$9,187Anne BealIndividual224US$41.01
23 Sep 24BuyUS$73,862Charles BancroftIndividual1,801US$41.01
23 Sep 24BuyUS$9,187Tsun-Huei LeeIndividual224US$41.01
23 Sep 24BuyUS$9,146Elizabeth AndersonIndividual223US$41.01
23 Sep 24BuyUS$9,187Jesse GoodmanIndividual224US$41.01
20 Jun 24BuyUS$48,062Vishal SikkaIndividual1,179US$40.76
20 Jun 24BuyUS$9,131Hal BarronIndividual224US$40.76
20 Jun 24BuyUS$9,172Harry DietzIndividual225US$40.76
20 Jun 24BuyUS$9,172Anne BealIndividual225US$40.76
20 Jun 24BuyUS$73,825Charles BancroftIndividual1,811US$40.76
20 Jun 24BuyUS$9,172Elizabeth AndersonIndividual225US$40.76
20 Jun 24BuyUS$9,172Jesse GoodmanIndividual225US$40.76

Insider Trading Volume

Insider Buying: GSK insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of GSK?
Owner TypeNumber of SharesOwnership Percentage
Public Companies1,564,7140.0383%
Individual Insiders3,457,9640.0847%
State or Government6,724,7390.165%
Private Companies45,170,1791.11%
Employee Share Scheme72,615,0081.78%
General Public455,332,05111.2%
Institutions3,495,635,04685.7%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 51.18% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.1%
Dodge & Cox
371,510,592US$6.3b-0.07%2.12%
8.77%
BlackRock, Inc.
357,711,118US$6.0b5.43%0.09%
4.72%
The Vanguard Group, Inc.
192,623,248US$3.2b-0.06%0.05%
2.24%
State Street Global Advisors, Inc.
91,396,808US$1.5b0.36%0.06%
2.05%
FMR LLC
83,853,987US$1.4b-7.8%0.08%
2.01%
Wellington Management Group LLP
81,929,159US$1.4b2.54%0.21%
1.89%
Legal & General Investment Management Limited
77,196,936US$1.3b-5.72%0.23%
1.85%
UBS Asset Management AG
75,593,565US$1.3b2.18%0.12%
1.85%
Norges Bank Investment Management
75,360,993US$1.3b-4.23%0.1%
1.78%
GlaxoSmithKline Employee Trust
72,615,008US$1.2b-0.31%no data
1.62%
Schroder Investment Management Limited
66,302,267US$1.1b-17.7%0.71%
1.44%
HSBC Global Asset Management (UK) Limited
58,589,264US$987.7m41.7%0.39%
1.26%
Mondrian Investment Partners Limited
51,534,667US$868.8m11%5.78%
1.2%
Silchester International Investors LLP
49,126,050US$828.2m0%3.18%
1.11%
GlaxoSmithKline plc, Shareview Client
45,170,179US$761.5m-2.3%no data
1.01%
Royal Bank of Canada Trust Company (Bahamas) Limited, Asset Management Arm
41,054,236US$692.1m-1.91%17.7%
0.99%
Fisher Asset Management, LLC
40,570,368US$683.9m0.13%0.27%
0.95%
Aviva Investors Global Services Ltd.
38,768,216US$653.6m-3.11%0.86%
0.84%
Strategic Advisers LLC
34,230,224US$577.0m0.53%0.22%
0.82%
Columbia Management Investment Advisers, LLC
33,357,473US$562.3m1.24%0.12%
0.79%
Royal London Asset Management Ltd.
32,361,697US$545.5m7.12%0.69%
0.75%
Franklin Resources, Inc.
30,557,016US$515.1m2.19%0.18%
0.73%
Causeway Capital Management LLC
29,934,107US$504.6m32.7%2.08%
0.73%
PRIMECAP Management Company
29,707,510US$500.8m2.36%0.36%
0.67%
Amundi Asset Management SAS
27,351,246US$461.1m-2.32%0.09%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 06:21
End of Day Share Price 2024/12/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

GSK plc is covered by 62 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kamla SinghAlphaValue
John EadeArgus Research Company
Odile RundquistBaader Helvea Equity Research